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IntroductIon
In critical care medicine, therapeutic gases have received 
growing attention. Gases have significant advantages, in-
cluding their low cost, relative abundance, and feasibility 
of administration, making them ideal potential therapies for 
critically-ill patients. Trials investigating inhaled carbon 
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monoxide (CO) to prevent rejection and inflammation fol-
lowing solid organ transplant are currently being conducted 
(Resch et al., 2005; Bathoorn et al., 2007). Preliminary 
results show that inhaled CO could be adopted for use in 
the intensive care unit (ICU) in less than 10 years (Robinson 
et al., 2009). 
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Because inhaled carbon monoxide (CO) provides potent anti-inflammatory and antioxidant effects against ischemia reperfusion injury, 
we hypothesized that treatment of organ donors with inhaled CO would decrease graft injury after heart transplantation. Hearts were 
heterotopically transplanted into syngeneic Lewis rats after 8 hours of cold preservation in University of Wisconsin solution. Donor rats 
were exposed to CO at a concentration of 250 parts per million for 24 hours via a gas-exposure chamber. Severity of myocardial injury 
was determined by total serum creatine phosphokinase and troponin I levels at three hours after reperfusion. In addition, Affymetrix 
gene array analysis of mRNA transcripts was performed on the heart graft tissue prior to implantation. Recipients of grafts from CO-
exposed donors had lower levels of serum troponin I and creatine phosphokinase; less upregulation of mRNA for interleukin-6, intercel-
lular adhesion molecule-1, and tumor necrosis factor-α; and fewer infiltrating cells. Although donor pretreatment with CO altered the 
expression of 49 genes expressly represented on the array, we could not obtain meaningful data to explain the mechanisms by which 
CO potentiated the protective effects.Pretreatment with CO gas before organ procurement effectively protected cardiac grafts from 
ischemia reperfusion-induced injury in a rat heterotopic cardiac transplant model. A clinical report review indicated that CO-poisoned 
organ donors may be comparable to non-poisoned donors. 
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Several previous studies (Nakao et al., 2003; Akamatsu 
et al., 2004; Nakao et al., 2006b; Nakao and Toyoda, 2012) 
have shown the feasibility of CO as a new therapeutic strat-
egy for organ transplantation. CO is well known for its high 
dose toxicology by binding to hemoglobin and displacing 
oxygen, leading to tissue hypoxia. However, CO is also 
known to be physiologically and endogenously generated 
in mammalian cells via heme catabolism in a rate-limiting 
step of heme oxygenase systems. CO powerfully protects 
against cellular injury (Otterbein et al., 1999, 2000; Ryter 
and Choi, 2010) and reduces inflammatory responses and 
ischemia/reperfusion (I/R) injury, which is obligate in the 
surgical procedure for heart transplantation and recognized 
as a major determinant of primary graft dysfunction. CO 
relaxes the blood vessels and exerts anti-thrombotic ef-
fects by hindering platelet aggregation and depressing 
fibrinolysis (Fujita et al., 2001). CO also inhibits apoptosis 
of epithelial and endothelial cells and reduces prolifera-
tion of T lymphocytes, fibroblasts, and smooth muscle 
cells (Nakao et al., 2006b). Therefore, collective evidence 
supports the idea that CO treatment applied to transplant 
organs, donors, or recipients can inhibit graft dysfunction 
from rejection or I/R injury (Nakao et al., 2003, 2006a; 
Nakao and Toyoda, 2012). Effects of organ protection 
through molecular biological signal transmission such as 
mentioned above were already provided, but changes in 
vivo gene expressions due to external environments are 
unclear. 
We believe that CO may play an important role in the 
ICU for potential organ donors in the near future. Further-
more, recent data demonstrated that CO-poisoned patients 
may be acceptable organ donors (Fujisaki et al., 2014), 
although additional studies, including human clinical trials, 
are absolutely warranted. Therefore, we hypothesized that 
prolonged CO pretreatment of a potential organ donor may 
reduce I/R injury of the cardiac grafts. This study was de-
signed to determine whether organs are suitable and secure 
for transplantation when donors in the ICU are treated with 
inhaled CO for a prolonged period.
MaterIals and Methods
animals
Male Lewis rats (LEW, RT1) weighing 200-250 g were 
purchased from Japan SLC Inc. (Shizuoka, Japan) and 
were kept in individual stainless steel cages in a tempera-
ture-, humidity-, and light-controlled room (23 ± 3°C, 55 
± 15%; 12-hour light-dark cycle) for 2-5 weeks before the 
experiments. During this period, all animals were provided 
standard food (AIN-93G diet; Oriental Kobo Corporation, 
Tokyo, Japan) and free access to water. All procedures 
involving rats were conducted in accordance with the 
guidelines of the Animal Care and Use Committees of the 
Hyogo College of Medicine and complied with the National 
Research Council’s Guide for the Humane Care and Use of 
Laboratory Animals.
co exposure
Donor animals were exposed to CO (250 parts per million 
(ppm)) in air in a stainless steel mixing cylinder and then 
directed into a 26 cm × 38 cm × 24 cm acrylic board ex-
posure chamber at a flow rate of 1.5 L/min. A CO analyzer 
(Taiyo, Osaka, Japan) was used to continuously measure 
CO levels in the chamber to maintain CO concentration at 
250 ppm. Animals were maintained in a CO chamber at a 
concentration of 250 ppm for the duration of the CO expo-
sure period with regular diet and water ad libitum. Carboxy-
hemoglobin was measured using an OSM3 Hemoximeter 
(Radiometer Copenhagen, Copenhagen, Denmark). After 
donor animals were treated with CO, blood carboxyhemo-
globin levels significantly increased 22.4% from 1.8% in 
the sham control groups.
heterotopic heart transplantation
We performed heterotopic heart transplantation as described 
previously (Ono and Lindsey, 1969; Nakao et al., 2010). 
Shortly after anticoagulation with 200 units of heparin, 3–5 
mL cold University of Wisconsin (UW) solution (Astel-
las Pharma Inc., Tokyo, Japan) was infused into the heart 
through the inferior vena cava to induce cardiac arrest and 
the heart grafts were excised. Excised grafts were stored 
in UW solution at 4°C for 8 hours and transplanted into 
the abdomens of recipient rats. Reanimation times from 
reperfusion to the start of sinus rhythm in the cardiac graft 
were monitored. At sacrifice, tissue and blood samples were 
fixed for histopathological analyses or snap-frozen in liquid 
nitrogen and kept at -80˚C until analyzed.
Experimental groups
Three experimental groups were examined. In the air group, 
the donors were kept in an air-contained gas exposure 
chamber for 24 hours (n = 18). In the CO group, the donors 
were maintained in the gas exposure chamber and exposed 
to 250 ppm of CO for 24 hours (n = 17). In addition to the 
transplant groups, naïve animals were used as sham opera-
tion rats (n = 6).
Measurement of myocardial injury
Serum total creatine phosphokinase (CPK) was assayed 
using a Beckman autoanalyzer (Beckman Instruments, Ful-
lerton, CA, USA). We evaluated the gross morphologyof the 
grafts with their identities masked and assigned a transplant 
score based on color (1: dead; 2: dark; 3: partially dark; 4: 
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grafts was studied. Graft tissue was collected for analysis 
after 24 hours preservation (prior to implantation into the 
recipient). Changes in gene expression in the grafts taken 
from the donors exposed to CO for 24 hours were compared 
to those taken from the donors treated with air. Total RNA 
from whole transplanted heart specimens was obtained 
using TRIzol® Reagent according to the manufacturer’s 
recommended protocol. RNA was dissolved with RNAase 
free water and refined to appropriate RNA concentration. 
Subsequent Agilent microarray processes were committed 
to Takara Bio Inc. (Shiga, Japan) on three rat specimens 
per group (air group and the inhaled CO group). Results of 
microarray data were thresholded using a false discovery 
rate (FDR) of 0.1 (Benjamini and Hochberg, 1995).
statistical analysis
Results are expressed as mean with standard error. All data 
were analyzed using SPSS Version 12 statistical software 
(SPSS Inc., Chicago, IL, USA). When analysis of variance 
(ANOVA) indicated a significant overall effect, differences 
among individual means were assessed using the Bonferroni 
post hoc test for multiple comparisons. A P value of < 0.05 
was considered statistically significant.
results
donor pretreatment with CO attenuated 
ischemia/reperfusion myocardial damage of the graft
Myocardial injury severity was determined by serum tropo-
nin I and CPK levels at 3h after reperfusion. With prolonged 
preservation for 8 hours, serum CPK levels increased to 
4,265 ± 477 from 178.3 ± 33.1 IU/L in normal animals. 
Donor CO pretreatment significantly reduced CPK levels 
to 2,132 ± 353 IU/L. Similarly, serum troponin I concen-
trations of the recipients that received air-treated grafts 
increased to 154 ± 53.1 IU/L 3 hours after reperfusion, while 
the troponin I levels of naïve animals were 10.7 ± 6.2 IU/L. 
On the other hand, serum troponin I levels of the recipients 
that received CO-treated grafts 3 hours after reperfusion 
were significantly lower (76.3 ± 14.9 IU/L) compared to 
those with untreated grafts (Figure 1).
co improved gross appearance of the cardiac grafts
To assess cardiac graft function, we evaluated the gross 
morphology of the grafts with their identities masked. Graft 
preservation in UW solution for 8 hours and reperfusion 
was associated with deterioration of the gross appearance 
of the cardiac grafts, resulting in prolonged reanimation 
time, darker color, weaker heart beat, and harder cardiac 
grafts. However, cardiac grafts taken from the donors pre-
treated with CO demonstrated quicker reanimation time 
and improved gross structural appearance, indicating earlier 
nearly healthy; 5: healthy or normal), contractility (1: dead; 
2: not much; 3: moderate function; 4: pretty good; 5: excel-
lent function or normal) and hardness (1: dead; 2:hard; 3: 
partially hard; 4:nearly soft; 5: soft or normal) at 6 hours 
post-reperfusion.
real-time reverse transcription-polymerase chain 
reaction (RT-PCR)
Total RNA was extracted from transplanted heart tissues 
employing TRIzol® Reagent (Life Technologies, Inc. 
Waltham, MA, USA). The mRNA levels of interleukin 
(IL)-6, intercellular adhesion molecule-1 (ICAM-1), tumor 
necrosis factor-α (TNF-α), inducible nitric oxide synthase 
(iNOS), endothelin (ET)1, vascular endothelial growth 
factor (VEGF), and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) were quantified using SYBR Green 2-step, 
RT-PCR in duplicate as previously described (Nakao et al., 
2003). Gene expression was normalized to GAPDH mRNA.
histopathological examination
For histopathological examination, heart grafts were har-
vested at six hours after transplantation and were fixed in 4% 
neutral buffered paraformaldehyde for 24 hours. The tissue, 
which was taken from the middle part of the left ventricle 
and stained with hematoxylin and eosin, was embedded in 
paraffin and sectioned at 3 μm thickness. Sections were also 
stained using a naphthol AS-D chloroacetate esterase stain-
ing kit (Sigma Diagnostics, St. Louis, MO, USA) for the 
presence of granulocytes according to the manufacturer’s 
instructions. Bright red-stained neutrophils infiltrated into 
the cardiac muscle cells and were counted by several people 
on the research team. Histopathological neutrophil counting 
analysis was executed with the samples’ identities masked. 
Grafted heart tissue was fixed in 4% paraformaldehyde, 
embedded in paraffin, cut into 3 μm sections, and incubated 
overnight at room temperature with mouse anti-rat CD68 
monoclonal antibody (ED-1, Serotec, Raleigh, NC, USA) 
to detect macrophages. A secondary antibody conjugated 
with the Histofine Simple Stain MAX-PO (Nichirei Biosci-
ence, Tokyo, Japan) was applied at room temperature for 
30 minutes. Visualization with diaminobenzidine (Liquid 
DAB+ substrate chromogen system; Dako Japan, Tokyo, 
Japan) was performed and then counterstained with Mayer’s 
hematoxylin. Slides were visualized with an Olympus DP72 
microscope (Olympus, Tokyo, Japan) and images were ac-
quired digitally. Positively-stained cells were counted with 
the samples’ identities masked. Data are presented as the 
number of positive cells per 400× high-power field (HPF).
Gene array analysis
The differential gene-expression pattern of the cardiac 
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after eight hours of cold storage and 3 hours of reperfusion. 
Pretreatment with CO inhibited the upregulation of TNF-α, 
IL-6, iNOS, and ICAM-1 mRNA levels. CO treatment did 
not affect the mRNA levels of ET-1. Interestingly, mRNA 
expression of VEGF significantly increased in the CO-
pretreated grafts three hours after reperfusion compared to 
that in the air-pretreated grafts (Figure 3).
Pretreatment with CO decreased the infiltration  of inflam-
matory cells
Routine histopathology of the graft samples 6 hours after 
reperfusion revealed variable levels of cellular infiltration. 
Grafted heart exposed to 250 ppm CO for 24 hours at-
tenuated neutrophil infiltration into cardiac myocytes. On 
the other hand, neutrophil count increased with statistical 
significance, especially in the air group compared to the 
functional recovery (Figure 2).
Pretreatment with co attenuated graft inflammatory response
I/R injury leads to early activation of inflammatory me-
diators such as proinflammatory cytokines and adhesion 
molecules. Intragraft mRNAs levels for TNF-α, IL-6, iNOS, 
ICAM-1, ET-1, and VEGF were significantly increased 
Figure 3: Real-time reverse-transcription polymerase chain reaction 
for inflammatory mediators in the cardiac graft tissue 3 hours after 
reperfusion.
Note: (A-F) Relative mRNA expression of TNF-α, ICAM-1, IL-6, ET-1, iNOS, and 
VEGF Values are expressed as mean ± SD. n = 5-6 for each group. *P < 0.05, 
vs. air group. CO: Carbon monoxide; TNF-α: tumor necrosis factor-α; ICAM-1: 
intercellular adhesion molecule-1; IL-6: interleukin-6; ET-1: endothelin1; iNOS: 
inducible nitric oxide synthase; VEGF: vascular endothelial growth factor; 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase.
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Figure 2: Macroscopic observations of cardiac grafts.
Note: (A) Time to reanimation after reperfusion. (B) Transplant score means 
total score added each following parameters, color, contractility and hardness. 
Each parameter scored on a scale of 1 to 4. n = 4 for each group, *P < 0.05, 
vs. air group. CO: Carbon monoxide.
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Figure 1: Serum creatinine phosphokinase (CPK) and troponin I levels.
Note: Severity of myocardial damage after reperfusion was determined by 
serum CPK (A) and troponin I (B) levels 3 hours after reperfusion and 8 hours 
after cold ischemia. Both serum CPK and troponin I levels were markedly 
elevated in the grafts of air group; however donor carbon monoxide (CO) 
treatment significantly reduced these serum markers of myocardial injury in the 
syngeneic recipients of grafts. Values are expressed as mean ± SD. n = 6-8 
for each group, *P < 0.05, vs. air group. HTx: Heart transplantation.
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sham group and CO group (Figure 4A).
Macrophages play important roles in cardiac I/R injury 
pathogenesis. Infiltrating macrophages (indicated by ED-
1-positive cells) were observed more often in the air-control 
group than in the CO-treated group 6 hours after reperfu-
sion, indicating that CO pretreatment inhibited the infiltra-
tion of macrophages (Figure 4).
Gene array
To compare and analyze gene expression in the heart tissue, 
Figure 4: Effect of carbon monoxide (CO) pretreatment on the infiltration of inflammatory cells in the cardiac graft tissue 6 hours after reperfusion.
Note: (A) A number of infiltrating naphthol-positive neutrophils and ED-1-positive macrophages were noted in the grafts taken from the air-control animals. There 
were fewer infiltrating cells in the grafts from the CO-pretreated donors. (B) Number of naphthol AS-D chloroacetate esterase-positive cells. (C) Number of ED-
1-positive cells. Values are expressed as the mean ± SD. *P < 0.05, vs. air group. ET-1: Endothelin1.
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we extracted genes and examined mean signal value and 
whether it significantly differed between the two groups (P 
< 0.05, q < 0.10). After filtering by signal value, 49 genes 
were isolated; large variance in particular revealed log2 
ratio > 1 or < -1 (Table 1). An undeniable gene associated 
with the anti-inflammatory response system and apoptosis 
pathway to prevent heart graft from I/R injury mechanism 
was not ascertained.
dIscussIon
Our results provide additional evidence that pretreatment of 
donors with low concentrations of CO confers cardioprotec-
tive effects in the clinically relevant setting of heart trans-
plantation. These beneficial effects were associated with 
the suppression of I/R-induced inflammatory responses.
Even though donor hearts are chosen carefully based on 
established and optimized donor selection criteria, primary 
graft dysfunction can still occur in patients receiving hearts 
from ideal donors. Heart grafts are exposed to numerous 
injuries before harvest, and many factors, including brain 
death, infection, shock, etc., may predispose them to pri-
mary graft dysfunction in the donor’s body. However, the 
likelihood of primary graft dysfunction is still difficult to 
predict, complicating recipient care. The I/R injury process 
is a complex sequelae concluding in pathophysiological 
features of persistent intrarenal vasoconstriction, injury of 
Table 1: Result of gene array in the graft heart tissue
Probe ID
Genbank 
accession Gene symbol 
LOG2 
ratio Description
Translation product or related 
protein
A_64_P082431
A_64_P065117
A_44_P654444
XM_574591
NM_001000072
XM_008763702
Olr1057
-2.27426
-1.62705
1.35428
Ssimilar to MAS-related G-protein 
coupled receptor, member G, 
transcript variant 2 (RGD1562011)
Olfactory receptor 1057 (Olr1057)
Nuclear receptor subfamily 4, 
group A, member 3 (Nr4a3), 
transcript variant X1
Angiotensin (1-7) 
receptor
Olfactory receptor
Nuclear receptor
G-protein 
coupled 
receptor
A_44_P416695
A_44_P380060
A_44_P1109819
NM_001004022
NM_001014154
XM_008767739
Krt15
Dnaaf1
LOC103693323
-1.90307
-1.80188
-1.56747
Keratin 15, type I (Krt15)
Dynein, axonemal, assembly factor 
1 (Dnaaf1)
Collagen alpha-1(XXIII) chain 
(LOC103693323)
Type I cytokeratin
Mortar protein
Type II 
transmembrane 
protein
Structural 
protein
A_43_P22106
A_44_P1116299
A_44_P1081870
A_44_P1085989
A_44_P118724
A_44_P118724
A_43_P11044
XM_003750328
XM_008773357
NM_001134593
NM_001109149
NM_019361
NM_019361
NM_001009632
Brwd3
Ciart
Nmb
Arc
Arc
G0s2
-1.80228
-1.48077
-1.38026
-1.37186
-1.36731
-1.35546
1.357051
Similar to C42C1.13 (LOC679247)
Bromodomain and WD repeat 
domain containing 3 (Brwd3), 
transcript variant X1
Circadian associated repressor of 
transcription (Ciart)
Neuromedin B (Nmb)
Activity-regulated cytoskeleton-
associated protein (Arc)
G0/G1 switch 2 (G0s2)
Methyltransferase 
like 21B
Histone modification 
and recognition
Transcriptional 
repressor
Bombesin-related 
peptide
Required for 
consolidation of 
synaptic
Anti-lypolytic factor
Functional 
protein
A_44_P1158015
A_64_P100793
XM_008759219
NM_021866 Ccr2
-1.66483
-1.42155
Coiled-coil glutamate-rich protein 
2 (Ccer2)
Chemokine (C-C motif) receptor 2 
(Ccr2)
Coiled-coil domain
Receptor for 
monocyte 
chemoattractant 
protein-1 
Receptor
 or domain
A_44_P364055
A_44_P666425
A_44_P219372
AA818208
AI059890
CA505509 G0s2
-1.74434
-1.46797
1.354726
cDNA clone UI-R-A0-ai-h-08-0-
UI 3'
cDNA clone UI-R-C1-la-e-12-0-
UI 3'
cDNA clone UI-R-FS1-cqf-j-05-0-
UI 3'
Unknown
A_44_P1132099
A_44_P1150680
XR_600177
XR_597280
LOC102547852
LOC103694352
-1.84172
-1.40984
Uncharacterized LOC102547852 
transcript variant X1
Uncharacterized LOC103694352
(ncRNA)
Note: The top 20 of 49 genes in which expression was significantly changed by carbon monoxide.
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previously unknown molecular changes that may underlie 
the beneficial effects of donor treatment with inhaled CO. 
The gene array showed several upregulated genes as well as 
downregulated genes. Although we carefully examined the 
expression of several of the upregulated/downregulated genes 
related to stress-response molecules or ATP-synthesis-related 
molecules, anti-apoptosis molecules, antioxidant molecules, 
and the transcription factors regulating their expression in 
our experimental setting, we could not obtain meaningful 
data to explain the mechanisms by which CO potentiated 
the protective effects. We assume that CO preloaded in the 
grafts may function after reperfusion in the recipient circu-
lation, which still remains elusive. Alternatively, CO might 
function effectively by binding to crucial heme proteins in 
excised grafts, as in our previous study (Nakao et al., 2008).
CO inhalation has been successfully demonstrated as a 
potential therapeutic in a number of animal models in the 
past decades and has now been tested in several phase I 
and/or II clinical trials, including those involving sepsis-
induced acute respiratory syndrome, aortic valve surgery, 
and pulmonary artery hypertension (Nakahira and Choi, 
2015). Thus, accumulating evidence shows that CO can be 
used for acute phase critically-ill patients. 
In conclusion, this study shows that donor inhalation 
of low doses of CO effectively mitigates the I/R injury of 
cardiac grafts through downregulation of proinflammatory 
mediators. Inhaled low-dose CO represents a novel and 
appealing therapy to prevent I/R injury for organ donor 
candidates. We believe that CO treatment of potential organ 
donors can maintain the current pool and increase the future 
pool of organs and tissues suitable for transplantation, which 
could have a substantial clinical impact.
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